Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Patients.

Yaounde Central Hospital24 enrolled

Overview

The aim of the study is to compare the short term effect of perindopril and zofenopril in the management of hypertension and the oxydative stress in blacks hypertensive patients. PEZO-HP is a double-arm, double-blind, randomized and parallel clinical trial conducted at the Yaoundé Central Hospital.

Aim: to determine and compare the short term effect of angiotensin converting in the management of hypertension as well as the oxidative effect of Zofenopril and perindopril in blacks hypertensive patients in the Yaoundé Central Hospital. Method: A double-arm, double-blind, randomized and parallel clinical trial conducted at the Yaoundé Central Hospital. Hypertensive patients who are not taking angiotensin-converting enzyme inhibitor or angiotensin receptors blockers, are randomize into 2 groups. Depending on the group, the intervention consisted of the administration of Perindopril 10 mg daily or Zofenopril 30 mg daily for 08 weeks. The endpoints were the nycthemeral blood pressure profile, pro oxidant marker (malondialdehyde) and anti-oxidant marker (Ferric reducing antioxidant). Progress: Recruitment for PEZO-HP was completed in May 2019 with 24 patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Hypertension

Interventions

Perindopril ArginineDRUG

10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.

Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomerDRUG

30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.

Eligibility

Sex: ALLMin age: 21 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hypertensive patients * On a stable atihypertensive therapies (determined by the investigator) for at least 3 months with no classes changes. The pharmacological treatment should not include an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker * Subject must not present any contraindication to exercise * Before any study-specific procedure, the appropriate written informed consent must be obtained. Exclusion Criteria: * Side effects affecting life quality of patients (determined by the Data Safety Monitoring Board). * Withdrawal of consent

Locations (1)

Yaounde Central Hospital, Cardiology department

Yaoundé, Cameroon

Outcomes

Primary Outcomes

Change in nycthemeral blood pressure profile (mmHg)

Change in nycthemeral blood pressure profile from baseline to week 08. By using Arterial Blood Pressure Monitoring.

Time frame: 8 weeks

Secondary Outcomes

Change in serum concentration of oxidant marker: malondialdehyde (micromol/l)

Change in concentration of oxidant marker from baseline to week 8. By spectrophotometer

Time frame: 8 weeks

Change in serum concentration of anti-oxidant markers: Ferric reducing antioxidant Power (micromol)

Change in concentration of anti oxidant marker from baseline to week 8. By spectrophotometer

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.